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http://www.virologyj.com/content/11/1/126RESEARCH Open AccessReactive astrogliosis in response to hemorrhagic
fever virus: microarray profile of Junin
virus-infected human astrocytes
Olga A Kolokoltsova, Nadezhda E Yun and Slobodan Paessler*Abstract
Background: Arenavirus Junin is the causative agent of Argentine hemorrhagic fever. Limited information is
available concerning the pathogenesis of this human disease, especially the pathogenesis of acute and late
neurological symptoms.
Methods: In our study we present for the first time cDNA microarray profile of human astrocytes infected with the
virulent strain of Junin virus. Transcriptional profiling was confirmed by quantitative real-time RT-PCR and
cytokine/chemokine/growth factor assay.
Results: We demonstrated the impact of virus infection on immune/inflammatory response/interferon signaling
and apoptosis. Pro-apoptotic response and amplification with time of pro-inflammatory cascade of human
astrocytes suggested neurodegenerative dysfunctional reactive astrogliosis in response to Junin virus infection.
Conclusion: Our results suggest potential pathogenic role of astroglial cells in the development of neurological
symptoms and late neurological syndrome during Argentine hemorrhagic fever.
Keywords: Interferon, Apoptosis, Inflammation, NeurodegenerationIntroduction
New World clade B arenavirus Junin [1] is the etiological
agent of Argentine hemorrhagic fever (AHF) [2], highly le-
thal disease endemic to the central Argentina [3]. Inhal-
ation of aerosolized rodent secreta and excreta or direct
contact with infected rodents of Calomys musculinus and
laucha spp, chiefly drylands vesper mouse, are the main
routes of infections among agricultural workers during
harvest season [3,4]. The disease case fatality rate is 15-
42% when untreated [5,6]. The highest level of biocontain-
ment (BSL-4) is required for the work with most of the
hemorrhagic fever viruses in the USA, including JUNV,
which hinders biological research in this field.
AHF is characterized by gastrointestinal, cardiovascular,
hematological, renal, immunological, hemorrhagic and
neurological manifestations [5,7]. As a matter of fact, many
patients infected with various hemorrhagic fever viruses
present with either acute or chronic neurological disorders.* Correspondence: slpaessl@utmb.edu
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article, unless otherwise stated.The pathogenesis of the disease remains elusive. Elevated
levels of IL-6, IL-8, IL-10 and TNF-α detected in AHF pa-
tients correlated with the disease severity [8,9]; while in-
creased concentration of G-CSF in serum of AHF patients
correlated with levels of TNF-α, IL-6, IL-8, and IL-10 [10].
In addition, elevated levels of IFN-α detected in patients
with AHF correlated with severity of disease, poor progno-
sis [11], fever, chills, backache [12], low platelet count and
platelet abnormality [13]. The source of these cytokines and
chemokines in response to JUNV infection in humans is
unclear. No induction of IFN-α, IFN-β, IL-6, IL-10, IL-12,
or TNF-α production was observed in ex vivo cultivated
human monocytes and macrophages upon infection with
pathogenic Romero strain of JUNV [14]. In contrast, re-
cently we demonstrated type I interferon (IFN) production,
IFN stimulated gene expression and STAT1 phosphoryl-
ation in JUNV Romero-infected human lung epithelial car-
cinoma cells. Additionally, we showed that in these cells
RIG-I/IRF3 signaling was responsible for type I IFN induc-
tion upon JUNV infection [15].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(10% of symptomatic case) [16], however underlying patho-
logical changes are not understood. Although, JUNV was
isolated from brain tissues obtained during autopsy of fatal
cases of AHF [17], no neuronal necrosis was observed [16].
Histopathological findings in the CNS of patients with
neurological cases of AHF also include severe meningeal
congestion, hemorrhage in Virchow Robin space, lympho-
cytic perivascular infiltrates in the brain and meninges
[17,18], diffuse microglial proliferation [17] and capillary le-
sions [16]. Moreover, a study of 10 autopsy cases of AHF
described focal and diffused glial cell proliferation and
edema in all patients, and brain microhemorrhages in
some. In contrast to the aforementioned autopsy report
[16], chromatolysis and pyknosis in neurons suggestive of
neuronal apoptosis and/or necrosis was detected in this
study [19].
JUNV is increasingly neurotropic in the most relevant
primate models of AHF [20-23]. Infectious virus was found
in the brains of New World primates Callithrix jacchus
intramuscularly infected with JUNV XJ strain. Brain path-
ology of the infected animals included lymphoreticular peri-
vascular cuffing, gliosis, and leptomeningitis. Viral antigen
was detected in the brain via immunostaining in the small
vessels endothelium, neurons and leptomeninges [20].
A late neurological syndrome (LNS) develops in 11% of
AHF survivors treated with convalescent serum [24,25].
No human pathology data exist to shed light on the mech-
anism of this complication. Modeling of LNS in the guinea
pig model provided some insights to the disease develop-
ment. Following intraperitoneal infection with Romero
JUNV, untreated guinea pigs succumbed to infection after
2 weeks with no apparent brain pathology. In contrast, an-
imals treated with JUNV-specific immune sera developed
hind leg paralyses 3 weeks post challenge. High titer of in-
fectious virus was found in the brain but not in the other
organs of those animals. Histopathological findings in-
cluded swollen vascular endothelium, encephalitic and
meningeal perivascular cuffs made of lymphocytes and
monocytes as well as infiltrates of macrophages and swol-
len astrocytes indicative of neuronal degeneration [26].
Similarly, JUNV XJ strain-infected immune serum treated
non-human primates Callithrix jacchus develop neuro-
logic complications including hind-limb paralysis. High
titer of infectious virus was found in the brain and lesions
consisting of perivascular mononuclear infiltrates and
neuronal necrosis were detected in the spinal cord of the
affected animals [27].
Since the pathogenesis of AHF is not clearly understood,
we utilized cDNA microarray technology to profile
in vitro transcriptional changes associated with JUNV in-
fection of human cells. Published pathology findings from
both humans with AHF and the relevant animal models
suggest that glial cells, particularly astrocytes, may play animportant role in the neurological disorders associated
with AHF. Accordingly, we have selected normal human
astrocytes (NHA), non-transformed, non-immortalized,
primary cells for transcriptional profiling upon infection
with the virulent strain of JUNV, Romero.
Materials and methods
Virus
The Romero strain of JUNV (GenBank accession nos.
AY619640 and AY619641) was obtained from Dr. Thomas
G. Ksiazek (Centers for Disease Control and Prevention,
Atlanta, GA). The virus was isolated from a patient and
passaged twice in fetal rhesus lung cells and once in Vero
cells [28]. Laboratory virus stock was obtained by amplifi-
cation in Vero E6 cells. Cell debris in supernatants were
filtered out through 0.45 μm HV Durapore Membrane
Stericup sterile vacuum filtration system (Millipore Corpor-
ation, Billerica, MA). Cleared supernatants were concen-
trated through 30 min centrifugation at 3220 × g using
Amicon Ultra-15 Centrifugal Filter Unit PLHK Ultracel-PL
Membrane, 100 kDa (Millipore Corporation, Billerica,
MA). All work with JUNV was performed at the University
of Texas Medical Branch BSL-4 facilities (Robert E. Shope
Laboratory) in accordance with institutional health and
safety guidelines and federal regulations [29].
Cell lines
Clonetics Normal Human Astrocytes cells were maintained
in ABM Astrocyte Basal Medium supplemented for a
complete growth with AGM SingleQuots (Lonza Walkers-
ville, Inc., Walkersville, MD). Vero cells (American Tissue
Culture Collection, Manassas, VA) were maintained in
minimum essential medium (MEM) supplemented with
10% fetal bovine serum and 1% Penicillin-Streptomycin
(10,000 U/mL).
JUNV replication in NHA
NHA from a single donor were seeded at a concentration of
5 × 105/35-mm dish. After a 4-h incubation at 37°C mono-
layers were infected at a multiplicity of infection (MOI) =
0.01, 0.1 or 1 PFU/cell and incubated for 1 h at 37°C. Fresh
medium was used for mock infection. The inoculum was
then replaced with growth medium. At selected times after
infection, supernatants were harvested, and virus titers de-
termined by a plaque assay on Vero cells as previously de-
scribed [30]. Data were analyzed by two-way ANOVA using
SigmaPlot 12.0 (Systat Software, Inc., San Jose, CA).
Total RNA preparation and GeneChip processing
NHA were seeded at 7.5 × 105 cells/60 mm dish in 4 mL
of growth medium. After 24 h, medium was removed and
cells were mock-infected or infected with JUNV Romero
for 1 h at an MOI = 5 in 0.5 mL of medium. Then,
medium was replaced for incubation of cells.
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TRIZOL Reagent (Invitrogen Corporation, Carlsbad, CA)
followed by the RNAqueous Mini and RNeasy-Free DNA-
ase Set (QIAGEN Inc., Valencia, CA) according to the pro-
tocols adapted from the manufacturer’s instructions. Total
RNA (0.5 μg) was subjected to GeneChip Expression Ana-
lysis (Affymetrix, Santa Clara, CA) according to the
manufacturer’s instructions [Expression Analysis Tech-
nical Manual, Section 2: Eukaryotic Sample and Array
Processing, Alternative protocol for One-Cycle cDNA
synthesis followed by synthesis of biotin-labeled cRNA
with MessageAmp Premier RNA Amplification Kit
(Ambion Inc, Austin, TX)] in the Molecular Genomics
Core (University of Texas Medical Branch, Galveston,
TX). Total fragmented cRNA (10 μg) was hybridized to
the Affymetrix Human Genome GeneChip array U133A
2.0 using the GeneChip Hybridization Oven 640. The
chips were washed and stained in a GeneChip Fluidics
Station 450 and fluorescence was detected with an
Affymetrix-GS3000 Gene Array scanner using the
GeneChip Operating System software (GCOS1.4).
Microarray analysis
Microarrays quality assessment, preprocessing and differen-
tial expression analysis were performed with Bioconductor
software packages [31] in R programming environment [32].
Microarray quality was assessed with affy [33], affyPLM [34]
and QCReport packages. Log2 scale expression measures
were generated using the gcRMA algorithm of preprocess-
ing [35] using the gcrma package. General similarity in ex-
pression patterns of preprocessed microarrays was assessed
by principal component analysis using the affycoretools
package. The detection calls (present, marginal, or absent)
for each probe set were obtained using the mas5calls func-
tion in the affy package [33]. Only genes with at least one
present call across all samples were included.
Differential gene expression was analyzed using limma
package by fitting a linear model to the data to estimate
the variability and by using an empirical Bayesian method
to moderate the standard errors of the estimated log-fold
changes for statistical analysis and assessing differential
expression [36]. The moderated t-statistic associated P-
values derived from the linear-model analysis were ad-
justed for multiple testing according to Benjamini and
Hochberg’s method to control the false discovery rate
(FDR) [37]. The smallest adjusted P-value among control
and spike-in probe sets, which should not be differentially
expressed, was used to define P-value cutoffs. The FDR
(setting the P-value < 0.0005 avoided selecting any of the
control probe sets as differentially expressed) and a log2-
fold change > 1 was used to obtain the list of differentially
expressed genes.
Hierarchical clustering was performed on a set of differ-
entially expressed genes using the Spotfire DecisionSite9.0 for Functional Genomics (Spotfire Inc., Somerville
MA). The pairwise clustering algorithm employed the
Unweighted Pair-Group Method with Arithmetic Mean
method and defined the similarity between clusters by their
Euclidian distance [38]. Both probe sets (rows) and chips
(columns) were blindly clustered, with the final order deter-
mined by average values and not by input order.
Gene functionality of differentially expressed genes
was analyzed using the functional analysis tool of the
Ingenuity Pathways Analysis (Ingenuity Systems, www.
ingenuity.com). Differentially expressed genes were as-
sociated with biological functions and/or diseases in
Ingenuity’s Knowledge Base. Right-tailed Fisher’s exact
test was used to calculate a P-value determining the
probability that each biological function and/or disease
assigned to that data set is due to chance.
Differentially expressed transcripts were associated with
canonical pathways that were most significant to the data
set in Ingenuity Knowledge Base. The significance of the
association between the data set and the canonical path-
way was measured in two ways: A ratio of the number of
molecules from the data set that map to the pathway di-
vided by the total number of molecules that map to the
canonical pathway displayed. Fisher’s exact test was used
to calculate a P-value determining the probability that the
association between the genes in the dataset and the ca-
nonical pathway is caused by chance.
To identify an effect of transcriptional changes on bio-
logical functions Ingenuity Pathways Analysis Downstream
Effects analytic was implemented. The downstream effects
analysis was based on prior knowledge of expected causal
effects between genes and biological functions stored in the
Ingenuity Knowledge Base. The increase/decrease of bio-
logical function in response to detected transcriptional
changes was concluded based on the activation z-score and
P-value calculated with the Fischer’s exact test.
To identify the upstream transcriptional regulators re-
sponsible for the observed gene expression changes the In-
genuity Pathways Upstream Regulator Analysis was used.
The analysis was based on prior knowledge of expected ef-
fects between transcriptional regulators and their target
genes stored in the Ingenuity Knowledge Base. The analysis
examined the number of each transcription regulator tar-
gets and their direction of change to what is expected from
the literature. The upstream transcriptional regulators were
selected based on the activation z-score and P-value calcu-
lated with the Fischer’s exact test.
Quantitative real-time RT-PCR (qRT-PCR)
cDNA synthesis and PCR amplification were performed
with iScript cDNA Synthesis Kit and iQ SYBR Green
Supermix (Bio-Rad, Hercules, CA) according to the manu-
facturers’ instructions. Real-time PCR was performed on
CFX96 Real-Time PCR Detection System (Bio-Rad,
Kolokoltsova et al. Virology Journal 2014, 11:126 Page 4 of 13
http://www.virologyj.com/content/11/1/126Hercules, CA). The “Baseline Subtracted Curve Fit” ana-
lysis mode with user defined baseline and threshold values
was used to determine the geometric mean of the thresh-
old cycle (Ct) using CFX Manager Software Version 1.5
(Bio-Rad, Hercules, CA). To control for variation in input
RNA quantities and reverse transcription efficiencies, Ct
values were normalized to the average Ct values of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
actine β (ACTB) housekeeping genes. Melt curve analysis
of the PCR products was used to confirm specificity.
Primers were designed from target mRNA sequences ob-
tained through NetAffx Analysis Center (Affymetrix, Santa
Clara, CA) using NCBI/Primer-BLAST software [39]. The
qRT-PCR primer pair sequences will be supplied upon re-
quest. ΔΔCt based fold-change calculations and statistical
analysis (Student’s t-test) of quantitative real-time RT-PCR
data were performed at the RT2 Profiler™ PCR Array Data
Analysis Web Portal (http://www.sabiosciences.com/pcr/
arrayanalysis.php).
Quantification of cytokines, chemokines, and growth
factors in supernatants
NHA astrocytes were plated and infected as described in
Total RNA preparation and GeneChip processing. Super-
natants were harvested at 0, 24 and 96 h p.i. and processed
using Bio-Plex Pro™ human cytokine 27-plex immunoassay
(Bio-Rad, Hercules, CA) according to the manufacturers’
instructions. Concentration of the following factors were
assayed: basic FGF, G-CSF, GM-CSF, PDGF-BB, VEGF, IL-
1β, IL-1ra, IL-2, IL-6, IL-7, IL-8, IL-9, IL-15, IL-12 (p70),
IL-4, IL-5, IL-10, IL-13, IL-17, eotaxin, IP-10, MCP-1
(MCAF), MIP-1α, MIP-1β, RANTES, IFN-γ, TNF-α.
Quantification of IFN-β in supernatants
Next day after plating 1 × 104 NHA cells were mock-
treated or treated with ranging concentrations of Poly(I:
C)-LMW/LyoVec (InvivoGen, San Diego, CA) per manu-
facturers’ instructions. Next day after plating 1 × 104 NHA
cells were mock-infected or infected with VEE TC-83 virus
for 1 h at an MOI = 0.1 PFU/cell. At 24 h posttreatment
or post infection (p.i.) cells supernatants were collected
and concentration of human IFN-β was assayed by sand-
wich ELISA method using VeriKineTM Human IFN-Beta
ELISA Kit (PBL Assay Science, Piscataway, NJ) according




To determine the susceptibility and potential kinetics of
JUNV replication in astrocytes, we infected NHA cells at
a multiplicity of infection (MOI) of 0.01, 0.1 and 1.0
PFU/cell, and then collected virus supernatants for virus
titration every 24 h over a period of 6 days (Figure 1A).No production of infectious virus was detected during the
first 24 h p.i. Production rose exponentially during the fol-
lowing 72 h, peaking 96 h p.i. Levels of JUNV (Romero
strain) were slightly higher (although statistically insignifi-
cant) for the lower initial MOI; however, production kinet-
ics were similar among the different inoculations. These
data indicate that JUNV is capable of infecting NHA,
resulting in high yields of infectious virus.
Microarray analysis of NHA infected with JUNV
To gain insight into the response of human glial cells to
JUNV infection, we performed a microarray study of the
transcriptional changes that occur in infected and mock-
infected NHA cells. Tissue culture triplicates of NHA
were infected or mock-infected with JUNV at an MOI of 5
PFU/cell. Based on the kinetics of JUNV replication in
NHA, two time points were chosen for microarray ana-
lysis. The first time point at 24 h p.i. represented an early
time point associated with establishment of infection,
while the second time point at 96 h p.i. allowed us to pro-
file transcriptional changes related to JUNV infection after
overcoming host defenses. Furthermore, the transcrip-
tional state of cells can be affected by cellular proliferation
or by reaching confluency. In order to minimize the con-
founding effects of time-associated changes, we compared
gene expression data from the infected samples at each
time point with the corresponding mock-infected control.
At 24 and 96 h p.i., total RNA was isolated from NHA
cells infected with JUNV or mock-infected and was sub-
jected to GeneChip expression analysis. A list of differen-
tially expressed genes, which possess low probability values
adjusted for multiple testing (P < 0.0005) and log2-fold
changes of more than 1, was obtained as described in the
Materials and Methods. At 24 h p.i., 3 transcripts were
more than 2-fold down-regulated and 92 transcripts were
more than 2-fold up-regulated in the JUNV-infected NHA,
compared with mock-infected controls. At the 96 h p.i.
time point, a total of 112 differentially expressed genes were
down-regulated and 266 were up-regulated. Of these, 21
transcripts were up-regulated at both time points. The
number of up-regulated, differentially expressed transcripts
in JUNV-infected cells was higher than that of down-
regulated genes at both time points.
The entire dataset of differentially expressed genes was
further subjected to functional analysis through associ-
ation with biological function/disease and canonical path-
ways. An effect of transcriptional changes on biological
functions as well as the upstream transcriptional regula-
tors responsible for the observed gene expression changes
were identified. Genes that were differentially expressed in
the JUNV-infected NHA compared to mock-infected con-
trols belonged to many different gene categories, including
those involving the host immune response, apoptosis and
cell cycle. Apoptosis genes and immune response genes,
Figure 1 JUNV productive infection of NHA leads to amplification with time of immune/inflammatory response. A. JUNV production in
NHA. Cells were infected with the virus at indicated MOIs and supernatants were harvested daily. Production of infectious virus was measured by
plaque assay. B, C. Heat map plot of differentially expressed Immune/Inflammatory (B) and IFN (C) signaling transcripts for 24 and 96 h p.i. Rows
are arranged by hierarchical clustering following Z-score transformation of the normalized data. Columns represent mock-infected (M24 and M96)
and JUNV-infected (J24 and J96) tissue culture triplicates at 24 and 96 h p.i., respectively. Blue and green notches represent differentially expressed IFN
signaling transcripts for 24 and 96 h time points p.i., respectively. D. Volcano plots of microarray results with identification of differentially expressed
IFN-stimulated genes transcripts (red circles) for 24 (Di) and 96 (Dii) h p.i. The horizontal line represents significance (P < 0.0005) and the vertical lines
represent the change in gene expression of JUNV-infected NHA compared with that of Mock-infected cells [Log2(fold change) > 1].
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consistency of differential expression, number of differen-
tially expressed genes, and overall change.
Amplification of immune/inflammatory response during
JUNV infection
Genes regulated upon infection with JUNV were
grouped based on functional annotations. Over 23% (105
of total 452) of differentially expressed genes were catego-
rized as participating in several functionally overlapping
categories, which included antigen presentation, antimicro-
bial response, cell-mediated immune response, humoral
immune response, inflammatory response, organismal in-
jury and abnormalities, infection mechanism and infection
disease. We collectively named these categories the im-
mune/inflammatory response. We found 27 (out of 95
total) and 96 (out of 378) differentially expressed transcripts
that were classified as involved in the immune response at
both 24 and 96 h p.i., indicating increased cellular immune
response following JUNV infection (Figure 1B). Interest-
ingly, at 24 h p.i., all immune response-related transcripts
were up-regulated. At 96 h p.i., the majority of inflamma-
tory response transcripts were still up-regulated; however,
22 out of 96 transcripts were down-regulated (Figure 1B).
Of all immune response transcripts, 17 (out of the 27
total) at 24 h p.i., and 30 (out of the 96 total) at 96 h p.i.
could be categorized as related to the IFN signaling trans-
duction (JAK-STAT pathway) or induction [pattern recog-
nition receptors (PRR) involved in the recognition of
bacteria and viruses, RIG-I-like receptors involved in anti-
viral innate immunity and the activation of IRF by cytosolic
PRRs canonical pathways] (Figure 1C). Quite strikingly, all
IFN signaling transcripts were up-regulated at both time
points p.i. (Figure 1C, D). The most highly up-regulated
transcripts could almost all be categorized as related to the
IFN signaling (Figure 1D).
Differentially expressed IFN-stimulated transcripts in-
cluded those known to be up-regulated in response to type
I IFNs (IFIT1, IFIT3, MX1 and OAS) or associated with
type I induction (IRF7 and IRF9) (Figure 1C). In addition,
both Downstream Effects (Figure 2) and Upstream Regu-
lator (Additional file 1: Table S1) analyses confirmed an
induction of immune/inflammatory response and, particu-
larly, IFN signaling upon Romero JUNV infection. In
agreement with type I IFN signaling induction, biological
function related to viral replication were decreased while
Inflammatory and Neurological disease functions were
uniformly increased in Romero-infected NHA (Figure 2)
at 24 and 96 h p.i. For complete list of differentially
expressed gene for each function see Additional file 2:
Table S2 and Additional file 3: Table S3. Although no type
I IFN transcripts were up-regulated in Romero-infected
NHA (Figure 1B, C), IFNs α, β, λ and γ, IFN type I recep-
tor IFNAR1 and key transcriptional factors in induction oftype I IFN signaling including IRF-7, STAT1 and STAT2
were predicted to be activated (activation z-score ≥ 2 and
overlap P-value < 0.05) at both time points p.i. (Additional
file 1: Table S1).
In agreement with the role of RIG-I/IRF3 signaling in
type I IFN induction in response to JUNV infection [15],
an expression of RIG-I (DDX58) and IRF3-dependent
genes [40] [IFIT1 (ISG56); IFIT3 (ISG60, up-regulated at
24 h p.i.); ISG-15 (up-regulated at 96 h p.i.) were increased
in the infected cells (Figure 1C). Moreover, Upstream
Regulator analysis predicted an activation of RLH adapter
protein MAVS and key transcriptional factors (IRF-1,3,5)
involved into PRR-mediated induction of type I IFN at
both time points p.i. (Additional file 1: Table S1). By utiliz-
ing Bio-Plex multiplex system for the quantification of cyto-
kines, chemokines, and growth factors we showed that
production of RANTES, a product of another IRF3-regulated
gene [41], was elevated in supernatants collected from
Romero-infected NHA. Consistent with PRR-mediated NF-
κB signaling activation, we detected an increased production
of type I cytokines (IL-12, INF-γ), proinflammatory cytokines
(IL-6, TNF-α), chemoattractants and chemokines (IL-8, IP-
10, MCP-1) and growth factors (VEGF) in Romero-infected
NHA (Figure 3A).
Intriguingly, an expression of MYD88, a universal TLR
adaptor, was elevated in Romero JUNV-infected cells at 96
h p.i. (Figure 1C) and an activation status was assigned to
TLR3 and its adaptor protein TRIF at both times p.i. and
TLR4 at 96 h p.i. (Additional file 1: Table S1).
Although INF-γ was produced by JUNV-infected NHA
and multiple differentially expressed transcripts simultan-
eously linked to type I and II IFN response (e.g., IFI27,
IFI44, IFI44L, IFI6, IFITM1, ISG20, MX2 and IFI35) were
up-regulated in those cells, none of the transcripts specific
to type II IFNs were identified in our screen (Figure 1C).
These data suggested that type-I IFNs are the main anti-
viral signaling in human glial cells in response to JUNV
infection.
Validation of microarray data by qRT-PCR and ELISA
Selected genes from the microarray analysis were subjected
to validation by qRT-PCR to establish the extent to which
gene expression was modulated. Real-time PCR was carried
out using cDNA from JUNV-infected NHA and from
mock-infected control cells. Modulation of the specific
mRNA for 20 genes relative to the average expression of
GAPDH and ACTB housekeeping genes was assessed at
both times p.i. (Additional file 4: Table S4). The microarray
data highly correlated with those obtained by quantitative
real-time RT-PCR (Additional file 4: Table S4). The magni-
tude of upregulation was comparable between the two
methods, but was sometimes more extreme in qRT-PCR
than in microarray, possibly because quantitative real-time
PCR data are more accurate over a broader range.
Figure 2 (See legend on next page.)
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Figure 2 Predicted increase or decrease of biological functions in NHA in response to JUNV infection at 24 (A) and 96 (B) h p.i.
Significance of Downstream Effects analysis was based on combination of the activation z-score (-2 ≥ Z ≥ 2) and overlap P-value (P < 0.05). The
horizontal dashed lines represent activation z-score significance cutoff. Red and blue boxes highlight Infection Diseases and Cell Death
functions, respectively.
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tected as differentially expressed by microarray analysis.
To account for possibility of type II error we independ-
ently validated an expression level of IFN-β (IFNB1), im-
mediate early-phase (IFN-α4) and an autocrine activated
(IFN-α2) α-IFNs at both time points p.i. The levels of
IFN-α were not significantly different between JUNV-
infected and corresponding mock-infected samples as de-
tected by qRT-PCR (data not shown). Interestingly, using
the real-time PCR we found an elevated (above mock-
infected) level of expression of IFNB1 transcripts in
JUNV-infected samples: 17.02 fold (95% CI 0.00001, 39.75;
P-value 0.115666) at 24 h and 7.46 fold (95% CI 2.07,
12.85; P-value 0.033561) at 96 h p.i. However, an IFNB1
amplification product was undetectable in mock-infected
samples (average Ct values >40) and PCR product was
barely detected for infected samples (average Ct values of
36.73 and 36.47 at 24 and 96 h p.i. correspondingly) (data
not shown). The following indicates a low abundance of
IFNB1-coding RNA transcripts during JUNV infection,
considering that the initial load of cDNA was the max-
imum allowed by the assay. In agreement with low abun-
dance of IFNB1 transcripts, no elevation of IFN-β levels
above the background was detected by ELISA in the
supernatant of the infected and mock-infected samples at
both time points (data not shown). As detected by qRT-
PCR, increased levels of IFNB1 transcripts upon infection
correlates with induction of IFN-stimulated signaling reg-
istered in the microarray analysis. However, the low total
abundance of the transcript and secreted protein level
probably suggest that the initial peak of IFN-β induction
happened before 24 h p.i.
Additionally, we validated the integrity of type I IFN
signaling pathway in NHA by examining IFN-β produc-
tion through ELISA in these cells upon PRR stimulation.
In contrast to mock-treated cells, NHA showed a robust
IFN-β production upon poly(I:C) stimulation (Figure 3Bi)
or after infection with the TC-83 vaccine strain of Vene-
zuelan equine encephalitis virus (Figure 3Bii). These data
clearly confirm the unimpaired ability of NHA to mount
type I IFN response, however overall IFN-β production
was low (up to 100 pg/mL of medium).
Pro-apoptotic response of NHA to JUNV infection
Cell death genes comprised the other major category of
differentially expressed transcripts in JUNV-infected NHA
at 96 h p.i. Ingenuity Pathway functional analysis identified
cell death as the most significant (P-value <106) functionalgroup for the 96 h p.i., with over 34% (131 of total 378) of
differentially expressed transcripts implicated in the com-
plement system: induction of apoptosis by HIV; retinoic acid
mediated apoptotic signaling; death receptor signaling; p38
MAPK signaling; NF-κB signaling; and acute phase response
signaling canonical pathways (listed in the P-value increas-
ing order). According to the analysis, in the Romero-
infected cells, in the Cell Death and Survival functional
category, apoptosis of leukocytes, vascular endothelial cells,
lymphocytes, T lymphocytes, cardiomyocytes and blood
cells was uniformly increased (Figure 2, Additional file 2:
Table S2 and Additional file 3: Table S3). Among differen-
tially expressed cell death related genes, CASP6, CFLAR
(FLIP), FADD, IKBKB, TNFSF10 (TRAIL), and TRADD
transcripts were uniformly up-regulated at 96 h p.i. suggest-
ing the importance of classical Death Receptor Signaling
pathway for apoptosis induction JUNV pathogenesis (Fig-
ure 4). Additionally, at 96 h p.i. we found 7 differentially
expressed transcripts/genes (C3, C1R, C1S, CD55, CFH,
CFI and SERPING1) identified as part of the canonical path-
way of complement activation. Supportive of a proapoptotic
phenotype, expression of 6 of these transcripts was up-
regulated (C3, C1R, C1S, CFH, CFI and SERPING1). This
observation is consistent with complement system activa-
tion for the clearance of apoptotic cells in the brain [42]
(Figure 4).
In summary, gene transcriptional profile of JUNV-
infected NHA at 96 h p.i. shows a differential expression
of genes associated with programmed cell death. Ingenuity
Pathway Functional and Downstream Effects analyses sug-
gested an induction of programmed cell death with obvi-
ous directionality toward a pro-apoptotic phenotype in the
JUNV-infected NHA compared with the mock-infected
cells.
Discussion
We studied infection of NHA with the virulent strain of
JUNV and showed that human astrocytes are highly sus-
ceptible to infection. Susceptibility of NHA to JUNV in-
fection indicates the possibility that astrocytes might be
a source of virus production in the brain of patients with
AHF. Additionally, we analyzed the transcriptional re-
sponse of NHA to JUNV infection early and late post
challenge. To our knowledge, this is the first report of
JUNV-induced response in human astrocytes, and the
first study using mRNA profiling upon infection of hu-
man cells. Using transcriptional profiling that was partly
confirmed by qRT-PCR and cytokine/chemokine/growth
Figure 3 (See legend on next page.)
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Figure 3 Cytokines, chemokines, and growth factors production in NHA. A. Cytokines, chemokines, and growth factors production in NHA in
response to JUNV infection. Cells were mock-infected or infected with the virus and supernatants were harvested at 0, 24 and 96 h p.i.. Quantification
of cytokines, chemokines, and growth factors was performed by Bio-Plex multiplex assay. OOR>, out of standard range, above. Data represent the
average of 3 replicates ± SEM. B. IFN-β induction in NHA upon stimulation with poly(I:C) and vaccine strain of VEE virus. Cells supernatants were assayed
using human IFN-β ELISA. Bi. Cells were treated with ranging concentrations of Poly(I:C)-LMW/LyoVec or mock-treated. Bii. Cells were mock-infected or
infected with VEE TC-83 virus. Data represent the average of 3 technical replicates ± SD.
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on both immune/inflammatory response/IFN signaling and
apoptosis. Amplification of pro-inflammatory cascade with
time and pro-apoptotic response of NHA to JUNV infec-
tion are indicative of neurodegenerative dysfunctional re-
active astrogliosis [43,44]. In response to neurological
injury initial early astrocyte activation and reactive astro-
gliosis (astrocyte hypertrophy, proliferation, migration,
acute mild inflammation) represent CNS physiological
local response to limit the lesions, repair the initial dam-
age, regulate homeostasis, prevent neurodegeneration
and stimulate neurogenesis [45-47]. Indicative of astro-
cyte proliferation M phase Cell cycle function was in-
creased in Romero-infected NHA at 24 h p.i. (Additional
file 2: Table S2). On the other hand, massive/prolong
brain injury or astrocyte stress lead to amplification
of a microglia-astrocyte crosstalk and uncontrolled re-
lease of pro-inflammatory cytokines, chemokines and
reactive oxygen species that has been associated with
chronic neuroinflammation and neurodegeneration
[45,46,48-50].
Multiple anti- and pro-inflammatory cytokines (i.e.
IFN-α, IFN-β, IFN-γ, TNF-α, IL-1β, and IL-6), chemo-
kines [i.e. stromal cell derived factor-1 alpha (SDF-1α,
CXCL12), MCP-1, MIP-1α, RANTES and IP-10] and
growth factors are produced by activated astroglia in re-
sponse to an injury or pathogen [47]. Although, both
neurogenesis and neurodegeneration has been associated
with the factors produced by reactive astrocytes [49]; in
our study transcriptom and cytokine/chemokine/growth
factor profiles suggest the later response to JUNV infec-
tion. A link between chronic overproduction of type I
IFNs and neurodegenerative diseases has been well
established [50]. Likewise, we observed amplification with
time of type I IFN signaling in response to JUNV infec-
tion. Moreover, in NHA we found elevated production/ex-
pression of pro-inflammatory mediators [type I cytokines
(IL-12, INF-γ), proinflammatory cytokines (IL-6, TNF-α),
chemoattractants and chemokines (IL-8, IL-10, MCP-1,
RANTES)] but not anti-inflammatory cytokines (IL-4, IL-
5, IL-10, IL-13, IL-17) upon JUNV infection. However, at
24 h p.i. we detected an elevated expression of SDF-1a, a
key chemokine responsible for recruitment, proliferation
and survival of neuronal precursor cells, and an elevated
expression and production of FGF2 (BFGF) and VEGF at
24 and 96 h p.i. respectively (Figure 1, 3A) [49].Supportive of exacerbated pro-inflammatory astrogliosis,
Inflammatory and Neurological disease functions were
uniformly increased at both time points in the microarray
profile of JUNV-infected NHA. Among the others, neuro-
logical diseases such as relapsing-remitting multiple scler-
osis and progressive motor neuropathy were listed.
Pathogenic role of astrocytes in neurodegenerative disease
including Amyotrophic lateral sclerosis has been docu-
mented [46,48,50].
The transcriptional profile of Romero JUNV-infected
NHA indicated an apoptosis induction late in infection.
Correspondingly, earlier we demonstrated IFN-independent
RIG-I enhanced apoptosis induction in human and non-
human primate transformed cells in response to virulent
(Romero) and vaccine (Candid #1) strains of JUNV. Apop-
tosis induction in those cells was confirmed through quanti-
fication of phosphatidylserine translocation, Caspase 3
activation, Poly (ADP-ribose) polymerase (PARP) cleavage
and/or chromosomal DNA fragmentation [51]. In agree-
ment, activation of RIG-I/IRF3 pathway was evident in our
microarray profile.
Importance of three branches of Death Receptor Signal-
ing pathway CD95 (Fas)/CD95L (Fas L), TNF-TNFR1, and
TNF-related apoptosis-inducing ligand (TRAIL) and it re-
ceptors has been described for cell death induction in the
brain. Fas/FasL and TRAIL receptors are expressed by glia
and neurons and responsible for triggering neuronal and
astrocyte apoptosis; while Fas/FasL and TNF-TNFR1
pathways has been implicated in T-cell apoptosis induc-
tion [42,52,53]. In agreement with that, CASP6, CFLAR
(FLIP), FADD, IKBKB, TNFSF10 (TRAIL), and TRADD
transcripts were uniformly up-regulated at 96 h p.i. in
Romero-infected NHA.
Complement components produced by glia interact with
the apoptotic signals on the cell surface leading to comple-
ment receptor-dependent phagocytosis/clearance of apop-
totic cells [42,54]. Accordingly, C3, C1R, C1S, CFH, CFI
and SERPING1 encoding transcripts were up-regulated at
96 h p.i. in NHA infected with Romero JUNV. Detrimen-
tal inflammatory as well as neuroprotective role of com-
plement activation has been reported [54].
The recent study [43] reported transcriptional changes
of reactive astrocytes purified from mouse brains after is-
chemic stroke or LPS-induced neuroinflammation. Inter-
estingly, the transcriptional profile of Romero-infected
NHA in our study was similar to the detrimental pro-
Figure 4 Differential expression profile of transcripts categorized
as regulators of cell death of NHA infected with JUNV. Heat map
plot of differentially expressed cell death associated transcripts for 24
and 96 h p.i. Rows are arranged by hierarchical clustering following
Z-score transformation of the normalized data. Columns represent
mock-infected (M24 and M96) and JUNV-infected (J24 and J96) tissue
culture triplicates at 24 and 96 h p.i., respectively. Blue and green
notches represent differentially expressed cell death associated
transcripts for 24 and 96 h p.i. respectively.
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induced by LPS, but not to the beneficial or protective re-
sponse of reactive astrocytes in the ischemia model. Simi-
lar to our data, antigen presentation, complement, and
IFN pathways were induced in the LPS reactive astrocytes.
In contrast, increased metabolic activity, cell-cycle genes,
and transcription factors categories were more prominent
in reactive astrocytes from transient ischemia model [43].
In several previous studies of chronic encephalitis in
newborn rats and mice induced by JUNV intracerebral
inoculation or in vitro JUNV-infected rat and mouse as-
trocytes, a prominent astrocyte reaction to infection was
reported [55-64]. In contrast to JUNV infection of hu-
man astrocytes, a protective role of JUNV-stimulated
astrogliosis dependent on the increased expression of in-
ducible nitric oxide synthase (iNOS) and not associated
with the induction of apoptosis was reported in those
studies [58,63]. This discrepancy could be attributed to
the different mechanisms of JUNV interaction with cells
of resistant or permissive hosts.
Although limited, autopsy findings of patients with AHF
and pathology reports of AHF/LNS animal models suggest
gliosis/astrogliosis and neuronal damage as part of the dis-
ease pathogenesis [17,19,20,26,27]. Our observation of
neurodegenerative dysfunctional reactive astrogliosis in re-
sponse to virulent strain of JUNV infection is in agree-
ment with the human and animal model pathology.
Additionally, production of proinflammatory cytokines
(IL-6, TNF-α) and chemoattractant IL-8 by Romero-
infected NHA reflects systemic cytokine profile of severely
ill AHF patients [8,9]. Moreover, the transcriptional
changes of multiple genes involved in IFN signaling de-
tected in the JUNV-infected astrocytes partially corre-
sponded to the in vivo transcriptional changes of blood
mononuclear cells of Rhesus macaques infected with a
virulent strain of LCMV [65], furthermore suggesting the
relevance of in vitro profile observed in our study to the
in vivo response to JUNV.
In conclusion, our study clearly demonstrates for the
first time the high susceptibility of human astrocytes to in-
fection with hemorrhagic arenavirus. Additionally, our
mRNA profile of JUNV-infected human astrocytes con-
firmed by qRT-PCR and cytokine/chemokine/growth factor
assay suggests neurodegenerative dysfunctional reactive
Kolokoltsova et al. Virology Journal 2014, 11:126 Page 12 of 13
http://www.virologyj.com/content/11/1/126astrogliosis as a cellular response to this infection. Taken
together, our results suggest potential role of astroglial cells
in AHF pathogenesis, particularly pathogenesis of neuro-
logical symptoms and LNS.
Additional files
Additional file 1: Table S1. Predicted activated and inhibited upstream
transcriptional regulators in NHA infected with JUNV. Significance of
Upstream Regulator Analysis was based on combination of the activation
z-score (-2 ≥ Z ≥ 2) and overlap P-value (P < 0.05). Predicted activation
state is depicted in green for inhibited or in red for activated upstream
transcriptional regulators. Upstream transcriptional regulators that are
likely involved into regulation of gene expression at 24 h p.i. only are not
highlighted, at 96 h p.i. only are highlighted in light grey, at 24 and 96 h
p.i. – highlighted in dark grey.
Additional file 2: Table S2. Predicted increase or decrease of biological
functions in NHA in response to JUNV infection at 24 h p.i. Significance
of Downstream Effects analysis was based on combination of the
activation z-score (-2 ≥ Z ≥ 2) and overlap P-value (P < 0.05).
Additional file 3: Table S3. Predicted increase or decrease of biological
functions in NHA in response to JUNV infection at 96 h p.i. Significance
of Downstream Effects analysis was based on combination of the
activation z-score (-2 ≥ Z ≥ 2) and overlap P-value (P < 0.05). Cell death
functions are highlighted in grey.
Additional file 4: Table S4. High correlation of microarray and qRT-PCR
data for a subset of immune response genes. Confirmation of expression of
selected differentially expressed (array) IFN signaling genes at 24 and 96 h post
JUNV infection of NHA by qRT-PCR using cDNA from JUNV-infected NHA and
from mock-infected control cells. P-values originated from statistical analysis of
fold-changes for qRT-PCR are provided in the table. ND, not determined.
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